Belzutifan offers hope for patients with von Hippel-Lindau disease

The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.

5:00 AM

Author | Jordyn Imhoff

drawing in blue ink of kidneys on lined paper with lab note wording bottom right in blue with yellow background
Michigan Medicine

Patients with von Hippel–Lindau disease, a genetic condition brought on by a mutation in the VHL gene that predisposes the carrier to developing different kinds of tumors, have a high incidence of cancers, like kidney cancer. This is because of an inactive VHL gene that leads to hypoxia signaling, a condition that results from an imbalance between cellular oxygen consumption and blood flow.

Traditionally, invasive procedures like kidney and brain surgery were the only option for patients who produce these tumors, but an international single-group study of 61 participants published in The New England Journal of Medicine offers hope for those with the rare disease with the drug Belzutifan, which the research team showed can shrink tumors and keep patients from having to undergo surgery.

The drug, which targets the molecular defect in the VHL gene by antagonizing the hypoxia signaling, produces few side effects (predominantly anemia and/or fatigue) and appears to have an anti-cancer effect, according to study author Tobias Else, M.D., an endocrinologist leading the Comprehensive Clinical Care Center for VHL at University of Michigan Health Rogel Cancer Center.

"In virtually all of the patients' kidney cancers, brain and pancreatic tumors, the tumors shrunk and the effect was long lasting," said Else.

These findings are especially important for patients who are at higher risk of losing vital organ function due to tumors, or who face this risk due to the need to undergo major surgery. Belzutifan provides an alternative to surgery and may even replace it at some point, which is Else's hope.

"Ongoing studies will further evaluate the effect of this drug on these patients' tumors, but this is an exciting start for anyone with a hereditary cancer syndrome," said Else. "Rare diseases don't often get the attention they deserve, and this work shows that bench to bedside research can truly change peoples' lives. It may even lead to FDA approval of an entirely new in-class drug."

This research was sponsored by Peloton Therapeutics, Inc. and funded by Merck Sharp and Dohme, a subsidiary of Merck; the Intramural Research Program of the National Institutes of Health, National Cancer Institute Center for Cancer Research; and a grant (UO1 CA236489) from the NCI. Identifier: NCT03401788.

Paper cited: "Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease," The New England Journal of Medicine. DOI: 10.1056/NEJMoa2103425

More Articles About: Lab Notes Basic Science and Laboratory Research Alternative Medicine Cancer: Cancer Types Cancer and Genetics Cancer Surgery Cancer Research Cancer Treatment Genetics Rogel Cancer Center Kidney Cancer Surgery Types All Research Topics
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories Illustration of hand holding list, with pill bottle in opposite and and small pic of doctor talking to patient
Health Lab
New urine-based test detects high grade prostate cancer, helping men avoid unnecessary biopsies
A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
Illustration of a microscope
Health Lab
Helpful enzymes vanish in many patients with antiphospholipid syndrome
Researchers recently revealed a new mechanism behind antiphospholipid syndrome that the investigators hope will eventually allow treatments to be targeted closer to the source of the problem.
Florescent image of a human ovarian follicle
Health Lab
Spatial atlas of the human ovary with cell-level resolution will bolster reproductive research
New map of the ovary provides a deeper understanding of how oocytes interact with the surrounding cells during the normal maturation process, and how the function of the follicles may break down in aging or fertility related diseases.
A CT scan of healthy lungs
Health Lab
Study reveals potential to reverse lung fibrosis using the body’s own healing technique
A recent U-M study uncovers a pathway utilized during normal wound healing that has the potential to reverse idiopathic pulmonary fibrosis.
Blue image of a microscopic helix strand
Health Lab
Researchers discover urine based test to detect head and neck cancer
At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests
White rat with pink eyes in a glass case
Health Lab
An updated rat reference provides more accuracy for research
An updated rat reference provides more accuracy for research; could help researchers using rat models for the study of DNA, RNA, evolution, or genes linked to disease risks